Med-Chemist : "Quintessential Medicinal Chemistry"
Monday, March 4, 2024
FDA Approves Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
›
TheracosBio announced the U.S. Food and Drug Administration (FDA) approval of Brenzavvy (bexagliflozin), an oral sodium-glucose cotrans...
Friday, March 1, 2024
FDA Approves Jaypirca (pirtobrutinib) for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
›
Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), announced the U.S. Food and Drug Administration (FDA) approved Jaypirc...
Thursday, February 29, 2024
FDA Approves Orserdu (elacestrant) for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
›
The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, announced the U.S. Food and Drug Administration ...
Tuesday, February 27, 2024
FDA Approves Jesduvroq (daprodustat) for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis
›
GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) approval of Jesduvroq (daprodustat), an oral hypoxia-inducible...
Saturday, February 24, 2024
FDA Approves Miebo (perfluorohexyloctane) Ophthalmic Solution for the Treatment of the Signs and Symptoms of Dry Eye Disease
›
Bausch + Lomb Corporation, announced that the U.S. Food and Drug Administration (FDA) has approved Miebo ™ (perfluorohexyloctane ophthalmic...
Thursday, February 22, 2024
FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
›
In continuation of my update on Lumryz Avadel Pharmaceuticals plc a biopharmaceutical company announced the U.S. Food & Drug Adminis...
Tuesday, February 20, 2024
FDA Approves Mydcombi (tropicamide and phenylephrine hydrochloride) Ophthalmic Spray for Inducing Mydriasis
›
In continuation of my update on phenylephrine hydrochloride Phenylephrine Tropicamide Eyenovia, Inc, announced the U.S. Food and Drug Admin...
Thursday, February 15, 2024
FDA Grants Accelerated Approval for Qalsody (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis Associated with a Mutation in the SOD1 Gene
›
Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approval of Qalsody (tofersen) 100 mg/15mL injection for...
Wednesday, February 14, 2024
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
›
In continuation of my update on aripiprazole Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announced ...
Tuesday, February 13, 2024
FDA Approves Uzedy (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
›
In continuation of my update on Uzedy (risperidone) Teva Pharmaceuticals, announced the U.S. Food and Drug Administration (FDA) approval...
Wednesday, February 7, 2024
FDA Grants Accelerated Approval to Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy
›
Travere Therapeutics, Inc. (Nasdaq: TVTX) announced the U.S. Food and Drug Administration (FDA) approval to Filspari ™ (sparsentan) to re...
Saturday, February 3, 2024
FDA Approves Veozah (fezolinetant) for the Treatment of Vasomotor Symptoms Due to Menopause
›
Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approval of Veozah (fezolinetant) 45 mg once daily for the tr...
‹
›
Home
View web version